Source - RNS
RNS Number : 7352J
Abzena PLC
13 September 2016
 

Abzena plc

 

Result of Annual General Meeting

 

Cambridge, UK, 13 September 2016: Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), the life sciences group providing services and technologies to enable better biopharmaceutical products, announces that at its Annual General Meeting held today at 10 am at its Cambridge office, all resolutions were duly passed on a show of hands.

 

Details of the votes received in relation to each of the resolutions (which are more particularly described in the Notice of Annual General Meeting dated 9 August 2016) are as follows:

 

Resol

 

Vote For

% In favour

Votes Against

% Against

Votes Abstain

% Abstain

Total Votes

1

107,142,224

100

0

0

0

0

107,142,224

2

107,140,805

99.99

1,419

0.00132

0

0

107,142,224

3

107,140,805

99.99

0

0

1,419

0.00132

107,142,224

4

107,140,805

99.99

0

0

1,419

0.00132

107,142,224

5

107,140,805

99.99

0

0

1,419

0.00132

107,142,224

6

107,140,805

99.99

1,419

0.00132

0

0

107,142,224

7

107,140,805

99.99

0

0

1,419

0.00132

107,142,224

8

102,566,175

95.73

4,574,630

4.26

1,419

0.00132

107,142,224

Percentage figures have been subject to rounding as considered appropriate.

 

The total number of ordinary shares of £0.002 each eligible to be voted at the Annual General Meeting was 137,130,555.

 

Enquiries:

 

Abzena plc

John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer

 

+44 1223 903498

Cenkos Securities (Nominated Adviser and Broker)

Ivonne Cantu

 

+44 20 7397 8900

N+1 Singer (Joint Broker)

Aubrey Powell / Liz Yong

 

+44 20 7496 3000

Instinctif Partners

Melanie Toyne Sewell / Rozi Morris

+44 20 7457 2020

[email protected]com 

 

 

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.

 

The term "Abzena inside" is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on "Abzena inside" products.

 

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).

 

·      Immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.

·      Contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.

·      Proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals.

·      Contract chemistry and bioconjugation business focused on ADCs and is establishing the capability to manufacture ADCs to GMP standards.

 

For more information, please see www.abzena.com 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGSFSFLDFMSELU